Isofol Medical Management

Management criteria checks 0/4

Isofol Medical's CEO is Petter Lindqvist, appointed in Jan 2024, has a tenure of less than a year. directly owns 0.04% of the company’s shares, worth €17.28K. The average tenure of the management team and the board of directors is 0.8 years and 0.8 years respectively.

Key information

Petter Lindqvist

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.04%
Management average tenureless than a year
Board average tenureless than a year

Recent management updates

Recent updates


CEO

Petter Lindqvist

less than a year

Tenure

Mr. Petter Segelman Lindqvist serves as Chief Executive Officer of Isofol Medical AB (publ) since January 09, 2024. He is Chief Executive Officer of Hamlet BioPharma AB (publ) (formerly known as Hamlet Pha...


Leadership Team

NamePositionTenureCompensationOwnership
Petter Lindqvist
Chief Executive Officerless than a yearno data0.040%
SEK 17.3k
Margareta Hagman
Chief Financial Officerless than a yearno datano data
Roger Tell
Chief Medical Officerless than a yearno datano data

0.8yrs

Average Tenure

Experienced Management: 5IU's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Jan-Eric Österlund
Independent Chairmanless than a yearSEK 996.00k0.40%
SEK 169.3k
Sten Nilsson
Independent Directorless than a yearno data0.0019%
SEK 820.3
Lars Lind
Independent Directorless than a yearSEK 29.00k0.25%
SEK 107.8k
Alain Herrera
Independent Directorless than a yearSEK 271.00kno data
Helena Taflin
Independent Directorless than a yearno datano data

0.8yrs

Average Tenure

77.5yo

Average Age

Experienced Board: 5IU's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.